Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase 3 trial of Alimta (pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer

Next Previous
Trial Profile

A randomized phase 3 trial of Alimta (pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GALES
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 19 Dec 2011 Biomarker analysis results published in Annals of Oncology.
  • 27 Aug 2009 Interim analysis results have been reported in the Journal of Clinical Oncology.
  • 12 Nov 2008 Status changed from discontinued to completed, as reported by clinicaltrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top